Core Viewpoint - Lantheus Holdings, Inc. has completed the sale of its SPECT business to SHINE Technologies, allowing the company to focus on its growing portfolio of PET radiodiagnostics and microbubbles while advancing its pipeline of radiopharmaceuticals [1][2]. Company Overview - Lantheus is a leading radiopharmaceutical-focused company dedicated to improving patient outcomes through innovative diagnostic solutions [29]. - The company has been providing radiopharmaceutical solutions for 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [29]. Transaction Details - The sale includes Lantheus' SPECT business, diagnostic agents such as TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite, as well as the manufacturing facility in North Billerica, Massachusetts, and related Canadian operations [1]. - Solomon Partners Securities, LLC acted as the financial advisor for Lantheus during this transaction, with Foley Hoag LLP and Ropes & Gray LLP serving as legal advisors, and Ernst & Young LLP providing financial and tax advisory services [3]. SHINE Technologies Overview - SHINE Technologies, LLC is an industry leader in next-generation fusion technology, focusing on safety, cost-efficiency, and environmental responsibility [30]. - The company has successfully commercialized fusion technology across various applications, including medical isotope production essential for diagnosing heart disease and cancer [31]. - SHINE is also pioneering nuclear waste recycling to enhance the sustainability of nuclear energy and aims to change energy production through commercializing fusion energy [32].